Form 13-F position report

OUTLOOK THERAPEUTICS INC COM N

Reported by MORGAN STANLEY

OTLK CUSIP 69012T206 Manager CIK 0000895421

Reported 61,465 shares, up 11,879 (24.0%) from the prior quarter.

Reported value 45.1%; share count 24.0% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q3 2022
Shares 61,465 Quarter-end amount reported
Reported value $74,000 Fair value at quarter end
Consecutive quarters held 8 Through Q3 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 54000
2022-03-31 93000
2022-06-30 51000
2022-09-30 74000
2022-12-31 102765
2023-03-31 175186
2023-06-30 350093
2023-09-30 32046
2023-12-31 198762
2024-03-31 142958
2024-03-31 0
2024-06-30 95098
2024-09-30 233512
2024-12-31 108470
2025-03-31 48158
2025-06-30 680958
2025-09-30 821
2025-12-31 9518
2026-03-31 783
2026-06-30 26960
2026-09-30 25847

Quarterly position history

How this manager's reported quarter-end position changed over time.

21 quarters
Quarterly reported position history for OUTLOOK THERAPEUTICS INC COM N held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 45,069 +28,113 (165.8%) < 0.01% $25,847 2026-11-13
Q2 2026 Added 16,956 +13,150 (345.5%) < 0.01% $26,960 2026-08-13
Q1 2026 Reduced 3,806 -2,218 (-36.8%) < 0.01% $783 2026-05-15
Q4 2025 Added 6,024 +5,249 (677.3%) < 0.01% $9,518 2026-02-13
Q3 2025 Reduced 775 -424,824 (-99.8%) < 0.01% $821 2025-11-14
Q2 2025 Added 425,599 +386,125 (978.2%) < 0.01% $680,958 2025-08-15
Q1 2025 Reduced 39,474 -17,918 (-31.2%) < 0.01% $48,158 2025-05-15
Q4 2024 Added 57,392 +13,663 (31.2%) < 0.01% $108,470 2025-02-14
Q3 2024 Added 43,729 +30,843 (239.4%) < 0.01% $233,512 2024-11-14
Q2 2024 Added 12,886 +913 (7.6%) < 0.01% $95,098 2024-08-14
Q1 2024 Reduced 0 -504,471 (-100.0%) 0 $0 2024-05-15
Q1 2024 New 11,973 +11,973 (0.0%) < 0.01% $142,958 2024-05-15
Q4 2023 Added 504,471 +359,467 (247.9%) < 0.01% $198,762 2024-02-13
Q3 2023 Reduced 145,004 -56,199 (-27.9%) < 0.01% $32,046 2023-11-15
Q2 2023 Added 201,203 +40,482 (25.2%) < 0.01% $350,093 2023-08-14
Q1 2023 Added 160,721 +65,569 (68.9%) < 0.01% $175,186 2023-05-15
Q4 2022 Added 95,152 +33,687 (54.8%) < 0.01% $102,765 2023-02-14
Q3 2022 Added 61,465 +11,879 (24.0%) < 0.01% $74,000 2022-11-14
Q2 2022 Reduced 49,586 -2,202 (-4.3%) < 0.01% $51,000 2022-08-15
Q1 2022 Added 51,788 +12,325 (31.2%) < 0.01% $93,000 2022-05-13
Q4 2021 Reduced 39,463 -195,464 (-83.2%) < 0.01% $54,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

79 managers reported OUTLOOK THERAPEUTICS INC COM N for Q3 2022.

Managers reporting OUTLOOK THERAPEUTICS INC COM N in Q3 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Reduced 6,856,495 -99,112 < 0.01% $8,364,000 7 qtrs
VANGUARD GROUP INC Reduced 5,617,406 -2,230 < 0.01% $6,853,000 15 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 2,063,699 +5,890 < 0.01% $2,517,000 14 qtrs
STATE STREET CORPORATION Added 1,949,069 +59,730 < 0.01% $2,378,000 6 qtrs
LVW Advisors LLC Unchanged 1,733,633 0 0.47% $2,115,000 14 qtrs
NORTHERN TRUST CORPORATION Added 976,344 +1,443 < 0.01% $1,191,000 11 qtrs
Nuveen Asset Management LLC Added 835,265 +8,351 < 0.01% $1,019,000 6 qtrs
VISTA FINANCE LLC Reduced 397,555 -622,815 0.59% $485,000 3 qtrs
THE BANK OF NEW YORK MELLON CORPORATION Added 357,907 +25,958 < 0.01% $437,000 11 qtrs
CHARLES SCHWAB INVESTMENT MANAGEMENT INC Reduced 329,255 -1,722 < 0.01% $402,000 7 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2022
Filed
November 14, 2022
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

Sole
23,492
Shared
0
None
37,973

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.